Safety-net hospitals and clinics that buy outpatient drugs at a federal discount would, for a narrow set of medicines, start paying full price upfront and waiting for a rebate instead, under a pilot the Health Resources and Services Administration is moving forward.
The agency issued the notice regarding the rebate model pilot on July 31 and published it in the Federal Register on August 3. Manufacturers must submit rebate plans to HRSA by August 24, with approvals expected by September 24 and the pilot scheduled to begin January 1, 2027.
The change sounds technical. For a rural hospital or community health center operating on thin margins, it is a question about how much cash has to sit in drug inventory before it comes back.
Program Behind the Change
The 340B Drug Pricing Program requires manufacturers to sell covered outpatient drugs at discounted prices to eligible providers, known as covered entities. Those include disproportionate share hospitals, critical access hospitals, rural referral centers, federally qualified health centers, Ryan White HIV/AIDS clinics and others serving large numbers of low-income and uninsured patients.
The savings are not restricted to specific uses. Covered entities apply them broadly, funding charity care, free or discounted medications, community health workers, and services that would not otherwise be financially viable. For many safety-net providers, 340B revenue is a structural part of the budget rather than a bonus.
The program has grown enormously. HRSA reports 340B purchasing rose from $53.7 billion in 2022 to more than $100 billion in 2025, an expansion the agency cites as its rationale for testing stronger oversight.
Under the current model, a covered entity buys at the discounted 340B price directly. Under the pilot, it would purchase at wholesale acquisition cost and receive a rebate equal to the difference between that amount and the 340B ceiling price.
Scope Is Narrower Than the Headline Suggests
The pilot is limited in ways that matter for assessing the stakes.
It applies only to drugs selected under the Medicare Drug Price Negotiation Program for initial price applicability years 2026 and 2027, roughly two dozen products, and applies regardless of payer or indication. Those drugs accounted for less than 5.5 percent of total 340B sales in 2025, with the remaining 94.5 percent expected to continue under upfront discounts.
Participation is voluntary for manufacturers. It is not voluntary for providers. Once HRSA approves a manufacturer's plan, participation becomes mandatory for all covered entities purchasing that manufacturer's selected drugs.
HRSA has built in some protections. Approved plans must give covered entities at least 90 days notice before implementation, and manufacturers must pay the costs of the information technology platforms providers use to submit claims data. The agency says it will monitor rebate requests, payment timing, claim denials, dispute outcomes and administrative burdens, publish interim summaries, and release a formal first-year evaluation by April 30, 2028.
The agency's stated purpose is deduplication, preventing a drug from receiving both a Medicare maximum fair price and a 340B discount, alongside transparency and program integrity.
Cash Flow Argument on Both Sides
HRSA's position is that the shift should not create a significant cash-flow burden given the narrow scope and the notice requirements. Hospital groups disagree sharply.
The American Hospital Association said in its statement on the pilot that the policy would force hospitals in rural and other underserved communities to spend more on bureaucracy and less on care, and that it is considering all available options to prevent the program from taking effect. Maureen Testoni, president and chief executive of 340B Health, has argued that rebates are bad policy that will harm safety-net hospitals.
The mechanics behind that objection are concrete. A provider buying at wholesale cost fronts the full price, then submits claims data and waits. If a rebate is denied or delayed, the provider absorbs the difference. Small facilities with limited working capital feel that more than large systems.
Not all stakeholders object. One patient advocacy group welcomed the shift, with Community Access National Network president and chief executive Jen Laws pointing to the program's growth past $100 billion as raising questions about compliance, accountability and transparency.
This is the second attempt. HRSA announced a similar pilot in mid-2025 and approved nine manufacturers, but the AHA and the Maine Hospital Association sued under the Administrative Procedure Act, and the agency withdrew the model before implementation. It then issued a request for information in February 2026 and received more than 2,400 comments.
Consequences That Could Reach Patients
Nothing changes for anyone filling a prescription this week, and no patient will see a different price at a pharmacy counter because of this pilot.
The pathway to households runs through provider finances. If 340B revenue becomes less predictable, the programs it funds are what typically get cut first: free or reduced-cost medication programs, patient assistance staff, transportation services, and outreach in communities without other providers. Those effects would appear gradually and would be difficult to attribute to any single policy.
Patients who currently receive discounted medications through a hospital or community health center program can ask whether that program is 340B-funded and whether the facility anticipates changes. Most will not have answers yet, since the pilot has not started.
Anyone struggling with prescription costs has options unrelated to this dispute: asking a prescriber about generic or therapeutic alternatives, asking a pharmacist to check cash prices against insurance, manufacturer patient assistance programs, and state pharmaceutical assistance programs.
The next milestones are the August 24 manufacturer deadline, September 24 approvals, and any further litigation. MedicalDaily will report which manufacturers participate and any court action.
The bottom line: HRSA will test paying 340B discounts as rebates for a small set of drugs beginning January 2027, manufacturers must apply by August 24, hospital groups say the change shifts cash-flow risk onto safety-net providers, a first attempt was withdrawn after litigation, and the practical effects on patients would be indirect and gradual.
Key Questions Answered
What is the 340B program? A federal program requiring drug manufacturers to sell covered outpatient drugs at discounted prices to eligible safety-net providers, including certain hospitals, community health centers and specialty clinics.
What would the pilot change? Instead of buying at the discounted price upfront, covered entities would purchase at wholesale acquisition cost and receive a rebate for the difference.
Which drugs are affected? Only drugs selected under the Medicare Drug Price Negotiation Program for 2026 and 2027, roughly two dozen products representing less than 5.5 percent of total 340B sales.
Is participation optional? For manufacturers, yes. Once HRSA approves a manufacturer's plan, participation becomes mandatory for covered entities buying that manufacturer's selected drugs.
What are hospitals objecting to? That fronting full price and waiting for rebates shifts cash-flow risk and administrative cost onto providers with limited working capital.
Has this been tried before? Yes. A 2025 version was challenged in federal court by the American Hospital Association and Maine Hospital Association, and HRSA withdrew it before implementation. This is the second attempt.
Will patients see different prices? Not directly. Any effect would come indirectly through provider budgets for programs such as discounted medications and patient assistance staff.
